To print: Select File and then Print from your browser's menu

Title: Multitarget Immune Therapy Improves Outcomes of Severe Lupus Nephritis

"Multitarget Immune Therapy Improves Outcomes of Severe Lupus Nephritis"

Washington, DC -- July 2, 2008 -- A new treatment using a combination of drugs targeting different parts of the immune system improves the recovery rate for patients with severe lupus involving the kidneys, according to a study in the [Journal of the American Society of Nephrology.

"In our study, multitarget therapy is shown to be superior to traditional therapy for inducing complete remission of class V+IV lupus nephritis, with few side effects," said lead author Lei-Shi Li, MD, Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.

"We considered that, since the impact of severe SLE [systemic lupus erythematosus] on the kidney involves various parts of the immune system, it is necessary to treat the different immune targets with a combination of immunosuppressant drugs."

The study included 40 patients with severe lupus nephritis (class V+IV). Patients were divided into 2 groups. The first group received the multitarget therapy, consisting of tacrolimus, mycophenolate mofetil, plus a steroid. The other group received standard, single-drug, treatment with cyclophosphamide.

The complete remission rate, with recovery of normal kidney function, was about 4 times higher among patients receiving the 3-drug combination. "For patients receiving multitarget therapy, the complete remission rate reached 65% at 9 months, versus only 15% under traditional therapy," said Dr. Li.

Some patients in both groups had partial remission, with some return of kidney function. Overall, 95% of patients in the multitarget therapy group had partial or complete remission, compared with 55% of patients in the single-drug therapy group. The rate of most adverse effects was also lower with multitarget therapy.

The authors stress that their study is only preliminary. The study includes a small group of patients from a single hospital, with a relatively short follow-up time. Larger randomised trials with longer follow-up are required.

SOURCE: American Society of Nephrology

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.